Header cover image

Hong Kong (HSI) Biotech Industry Analysis

UpdatedMar 18, 2024
DataAggregated Company Financials
Companies47
  • 7D8.3%
  • 3M-10.8%
  • 1Y-40.8%
  • YTD-11.2%

The Biotech industry is up 8.3% in the last week, with Sichuan Kelun-Biotech Biopharmaceutical up 28%. In the same time, ImmuneOnco Biopharmaceuticals (Shanghai) was down 16%. In the past year, the industry is down 41%. Earnings are forecast to grow by 30% annually.

Industry Valuation and Performance

Has the Hong Kong Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 18 Mar 2024HK$366.5bHK$47.5b-HK$20,433,312,530.0617.6x-17.9x7.7x
Wed, 14 Feb 2024HK$321.2bHK$46.8b-HK$20,174,942,054.9115.6x-15.9x6.9x
Fri, 12 Jan 2024HK$385.8bHK$46.9b-HK$20,262,766,347.0017.7x-19x8.2x
Sun, 10 Dec 2023HK$399.7bHK$46.9b-HK$20,222,468,345.0017.7x-19.8x8.5x
Tue, 07 Nov 2023HK$430.1bHK$45.3b-HK$19,010,469,517.0013.6x-22.6x9.5x
Thu, 05 Oct 2023HK$400.6bHK$45.0b-HK$19,133,521,889.0013.7x-20.9x8.9x
Sat, 02 Sep 2023HK$410.0bHK$45.2b-HK$16,778,616,585.0015x-24.4x9.1x
Mon, 31 Jul 2023HK$427.9bHK$35.5b-HK$23,380,251,031.0028x-18.3x12x
Wed, 28 Jun 2023HK$393.2bHK$35.4b-HK$23,290,725,942.0024.5x-16.9x11.1x
Fri, 26 May 2023HK$426.2bHK$36.1b-HK$23,813,255,373.0029.5x-17.9x11.8x
Sun, 23 Apr 2023HK$441.1bHK$36.9b-HK$24,127,461,338.0018.5x-18.3x11.9x
Tue, 21 Mar 2023HK$388.5bHK$32.4b-HK$35,354,889,097.0022.5x-11x12x
Thu, 16 Feb 2023HK$426.4bHK$34.7b-HK$35,071,947,871.0032.5x-12.2x12.3x
Sat, 14 Jan 2023HK$465.6bHK$35.1b-HK$35,473,049,138.0032.1x-13.1x13.3x
Mon, 12 Dec 2022HK$393.0bHK$33.6b-HK$33,953,988,397.0024.6x-11.6x11.7x
Wed, 09 Nov 2022HK$364.0bHK$33.8b-HK$32,491,041,863.0018.5x-11.2x10.8x
Fri, 07 Oct 2022HK$297.9bHK$34.0b-HK$32,534,263,068.0017.2x-9.2x8.8x
Sun, 04 Sep 2022HK$334.7bHK$34.6b-HK$33,887,082,201.0015.6x-9.9x9.7x
Tue, 02 Aug 2022HK$324.6bHK$32.9b-HK$46,359,653,984.0012.7x-7x9.9x
Thu, 30 Jun 2022HK$369.6bHK$33.0b-HK$46,590,730,202.0014.8x-7.9x11.2x
Sat, 28 May 2022HK$319.3bHK$34.0b-HK$45,701,495,668.0012.7x-7x9.4x
Mon, 25 Apr 2022HK$331.6bHK$35.8b-HK$45,369,217,033.0012.9x-7.3x9.3x
Wed, 23 Mar 2022HK$321.5bHK$34.9b-HK$35,543,106,551.0013.4x-9x9.2x
Fri, 18 Feb 2022HK$314.9bHK$31.2b-HK$31,991,144,778.0012.6x-9.8x10.1x
Sun, 16 Jan 2022HK$379.4bHK$31.1b-HK$31,846,983,742.0013.3x-11.9x12.2x
Tue, 14 Dec 2021HK$470.4bHK$31.1b-HK$31,827,233,997.0013.7x-14.8x15.1x
Thu, 11 Nov 2021HK$487.2bHK$31.0b-HK$31,676,947,042.0014.2x-15.4x15.7x
Sat, 09 Oct 2021HK$495.2bHK$30.5b-HK$31,535,187,052.0014.9x-15.7x16.2x
Mon, 06 Sep 2021HK$545.4bHK$30.4b-HK$31,412,511,864.3918.2x-17.4x17.9x
Wed, 04 Aug 2021HK$571.3bHK$30.2b-HK$32,058,827,347.3513.6x-17.8x18.9x
Sat, 08 May 2021HK$572.9bHK$27.8b-HK$26,637,487,691.0916.9x-21.5x20.6x
Price to Earnings Ratio

-19.3x


Total Market Cap: HK$513.3bTotal Earnings: -HK$26,637,487,691.09Total Revenue: HK$27.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Hong Kong Biotech Industry Price to Earnings3Y Average -14.8x202220232024
Current Industry PE
  • Investors are pessimistic on the Hong Kong Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 12.2x is higher than the industry's current PS ratio of 7.7x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Revenues for these companies have grown 20% per year.
  • This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.

Industry Trends

Which industries have driven the changes within the Hong Kong Healthcare industry?

HK Market1.55%
Healthcare4.12%
Biotech8.34%
Biotech8.34%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
6990 Sichuan Kelun-Biotech BiopharmaceuticalHK$147.1023.3%
+HK$6.1b
n/aPS19.7x
1801 Innovent BiologicsHK$42.305.8%
+HK$3.7b
11.6%PS12.6x
9926 AkesoHK$51.858.8%
+HK$3.5b
20.4%PE20.2x
9995 RemeGenHK$29.7523.7%
+HK$3.1b
-40.5%PS13.6x
2162 Keymed BiosciencesHK$39.3516.8%
+HK$1.6b
-36.6%PS30.6x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

2257

HK$8.00

Sirnaomics

7D

-25.9%

1Y

-85.5%

2511

HK$7.68

HighTide Therapeutics

7D

-10.4%

1Y

n/a

6660

HK$8.52

AIM Vaccine

7D

8.1%

1Y

-78.3%

1952

HK$26.40

Everest Medicines

7D

-7.7%

1Y

59.2%

2496

HK$7.95

Wuhan YZY Biopharma

7D

-6.9%

1Y

n/a

2157

HK$3.27

Lepu Biopharma

7D

-3.3%

1Y

-38.6%

2162

HK$39.35

Keymed Biosciences

7D

16.8%

1Y

-36.6%

2696

HK$14.96

Shanghai Henlius Biotech

7D

7.0%

1Y

27.9%

1541

HK$17.02

ImmuneOnco Biopharmaceuticals (Shanghai)

7D

-12.8%

1Y

n/a

6990

HK$147.10

Sichuan Kelun-Biotech Biopharmaceutical

7D

23.3%

1Y

n/a

9926

HK$51.85

Akeso

7D

8.8%

1Y

20.4%

9995

HK$29.75

RemeGen

7D

23.7%

1Y

-40.5%

1801

HK$42.30

Innovent Biologics

7D

5.8%

1Y

11.6%

1530

HK$5.40

3SBio

7D

6.9%

1Y

-32.4%

775

HK$0.40

CK Life Sciences Int'l. (Holdings)

7D

-5.9%

1Y

-47.4%

1877

HK$11.02

Shanghai Junshi Biosciences

7D

-5.8%

1Y

-61.1%